| European Federation of Internal Medicine

European Immunization Week 2018- Statement of Guido Rasi, Executive Director, European Medicines Agency

Posted on: 26/04/2018 - 13:27

Vaccines matter for each of us: yearly, they prevent 2.7 million people from contracting measles, one million from getting whooping cough and two million babies from getting tetanus. They eradicated smallpox. They stopped polio, a dreadful disease affecting millions of children, in almost all... more

Field of Interest: European Union Medical News

Type: News Feed

Referral: Levamisole-containing medicinal products, levamisole, associated names: Decaris,Levamisol Arena Article 31 referrals CMDh final position, 13/05/2026

Submitted by Anonymous (not verified) on 13 May 2026 - 16:29

Referral: Levamisole-containing medicinal products, levamisole, associated names: Decaris,Levamisol Arena Article 31 referrals CMDh final position, 13/05/2026

Read more about Referral: Levamisole-containing medicinal products, levamisole, associated names: Decaris,Levamisol Arena Article 31 referrals CMDh final position, 13/05/2026

Human medicines European public assessment report (EPAR): Lucentis, ranibizumab, Date of authorisation: 22/01/2007, Revision: 48, Status: Authorised

Submitted by Anonymous (not verified) on 13 May 2026 - 16:18

Human medicines European public assessment report (EPAR): Lucentis, ranibizumab, Date of authorisation: 22/01/2007, Revision: 48, Status: Authorised

Read more about Human medicines European public assessment report (EPAR): Lucentis, ranibizumab, Date of authorisation: 22/01/2007, Revision: 48, Status: Authorised

Tecovirimat SIGA

Submitted by Anonymous (not verified) on 13 May 2026 - 16:05

Tecovirimat SIGA

Read more about Tecovirimat SIGA

Ontozry

Submitted by Anonymous (not verified) on 13 May 2026 - 15:55

Ontozry

Read more about Ontozry

Human medicines European public assessment report (EPAR): Iclusig, ponatinib, Date of authorisation: 01/07/2013, Revision: 29, Status: Authorised

Submitted by Anonymous (not verified) on 13 May 2026 - 15:15

Human medicines European public assessment report (EPAR): Iclusig, ponatinib, Date of authorisation: 01/07/2013, Revision: 29, Status: Authorised

Read more about Human medicines European public assessment report (EPAR): Iclusig, ponatinib, Date of authorisation: 01/07/2013, Revision: 29, Status: Authorised

Human medicines European public assessment report (EPAR): Aspaveli, pegcetacoplan, Date of authorisation: 13/12/2021, Revision: 13, Status: Authorised

Submitted by Anonymous (not verified) on 13 May 2026 - 15:08

Human medicines European public assessment report (EPAR): Aspaveli, pegcetacoplan, Date of authorisation: 13/12/2021, Revision: 13, Status: Authorised

Read more about Human medicines European public assessment report (EPAR): Aspaveli, pegcetacoplan, Date of authorisation: 13/12/2021, Revision: 13, Status: Authorised

Human medicines European public assessment report (EPAR): EndolucinBeta, lutetium (177Lu) chloride, Date of authorisation: 06/07/2016, Revision: 11, Status: Authorised

Submitted by Anonymous (not verified) on 13 May 2026 - 15:06

Human medicines European public assessment report (EPAR): EndolucinBeta, lutetium (177Lu) chloride, Date of authorisation: 06/07/2016, Revision: 11, Status: Authorised

Read more about Human medicines European public assessment report (EPAR): EndolucinBeta, lutetium (177Lu) chloride, Date of authorisation: 06/07/2016, Revision: 11, Status: Authorised

Timetable: Initial (full) marketing authorisation application accelerated assessment timetables - Advanced therapy medicinal product (ATMP)

Submitted by Anonymous (not verified) on 13 May 2026 - 14:30

Timetable: Initial (full) marketing authorisation application accelerated assessment timetables - Advanced therapy medicinal product (ATMP)

Read more about Timetable: Initial (full) marketing authorisation application accelerated assessment timetables - Advanced therapy medicinal product (ATMP)

Timetable: Initial (full) marketing authorisation application accelerated assessment timetables

Submitted by Anonymous (not verified) on 13 May 2026 - 14:30

Timetable: Initial (full) marketing authorisation application accelerated assessment timetables

Read more about Timetable: Initial (full) marketing authorisation application accelerated assessment timetables

European Immunization Week 2018- Statement of Guido Rasi, Executive Director, European Medicines Agency

Referral: Levamisole-containing medicinal products, levamisole, associated names: Decaris,Levamisol Arena Article 31 referrals CMDh final position, 13/05/2026

Human medicines European public assessment report (EPAR): Lucentis, ranibizumab, Date of authorisation: 22/01/2007, Revision: 48, Status: Authorised

Tecovirimat SIGA

Ontozry

Human medicines European public assessment report (EPAR): Iclusig, ponatinib, Date of authorisation: 01/07/2013, Revision: 29, Status: Authorised

Human medicines European public assessment report (EPAR): Aspaveli, pegcetacoplan, Date of authorisation: 13/12/2021, Revision: 13, Status: Authorised

Human medicines European public assessment report (EPAR): EndolucinBeta, lutetium (177Lu) chloride, Date of authorisation: 06/07/2016, Revision: 11, Status: Authorised

Timetable: Initial (full) marketing authorisation application accelerated assessment timetables - Advanced therapy medicinal product (ATMP)

Timetable: Initial (full) marketing authorisation application accelerated assessment timetables

Newsletters

Latest Newsletters

You are here

Newsletters

Latest Newsletters